Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome

NCT02843659 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

45

Enrollment

INDUSTRY

Sponsor class

Stopped Inability to meet protocol objectives

Conditions

Sjögren's Syndrome

Interventions

DRUG: BMS-931699
DRUG: BMS-986142
DRUG: Placebo

Sponsor

Bristol-Myers Squibb